Collaborative Working Agreement Summary

1 Project Name:	Digitalisation of the VICTOR (Varying Insulin Doses for Changes TO Routine)
1. Project Name:	diabetes education programme
2. Organisations involved with this Joint Working Project are:	Eli Lilly and Company Ltd and Northumbria Healthcare NHS Foundation Trust
3. The objectives for this project are:	The objective of this project is to support the digitalisation of the VICTOR Programme which has been designed to meet the specific needs of People with Type 2 Diabetes (PwT2D) using insulin. Through the development of an easily accessible, virtual programme the project aims to increase levels of knowledge, skills and confidence of a diverse population of PwT2D on multiple daily injections from within existing DAFNE user sites (currently approx. 50% of NHS Trusts). Also, by developing a virtual offering, the project aims to increase the number of NHS Organisations wanting to use both VICTOR and DAFNE. This project covers the digitalisation of pre-existing VICTOR content which has been developed by the DAFNE team. It will include - Digitalisation of content (for example digital graphic design and animation) to improve the user experience. Achieved through the introduction to and use of Lilly approved 3 rd party graphic design vendors and the use of Lilly Green Room to film content. Evaluation of outcomes. i. Reach of VICTOR Courses ii. Evaluation of user experience for continuous improvement The project will run until the specified end date of 31 st March 2025 or until the platform goes live and outputs have been collected and published, whichever comes first.
4. Roles and Responsibilities, including any funding	 Roles and Responsibilities of Lilly UK: Development of Collaborative Working Agreement Documentation and certification in line with The ABPI Code of Practice 2021. Project management including developing a project plan, defining roles and responsibilities of all organisations, and planning timelines for delivery. Support procurement process for digital graphic design vendor by utilising Lilly preferred suppliers. Support with communication plan to scale VICTOR to HCPs and NHS centres across the UK. Support with development of feedback and audit tools to measure
	 project outcomes as per section 3. Publication of outcomes in relevant trade and clinical press and the Lilly corporate website. Lilly will not be involved in the development of any of VICTOR course content. DAFNE will retain full editorial independence of all content. Lilly will not be involved in the collection or analysis of any clinical data and will not be in receipt of any patient identifiable data.

Collaborative Working Agreement Summary

	Roles and Responsibilities of Northumbria Healthcare NHS Foundation Trust:
	 Understanding of the Northumbria Healthcare NHS Foundation Trust governance policy for entering into this Collaborative Working Agreements with Lilly. Creation of VICTOR clinical content for digitisation. Prepare a proposal for digital graphic design vendors to pitch against. Be responsible for content upload to the DAFNE platform and manage the existing relationship with The Open University to support this. Lead on the development of feedback and audit tools to measure project outcomes as per section 3. Healthcare professionals are responsible for reporting any Adverse Events identified using their NHS organisation's usual procedure. Ensure patient confidentiality at all times. No patient identifiable data should ever be shared with Lilly. Support publication of outcomes.
	Financial details Both parties will aim to match financial input into the project. The total cost of the project, both monetary costs and benefit-in-kind, will be calculated at project end for Transfer of Value reporting purposes. These have been estimated as £8,000 for Lilly staffing resource & £15,000 for DAFNE staffing resource (see benefit in kind cost breakdown on attached project plan for further detail). Lilly and DAFNE will each provide partial funding for costs associated with digital services. As these costs cannot be estimated with any certainty at project start Lilly will cap their contribution to these costs at £15,000. DAFNE input into these costs to be confirmed but are estimated to be in excess of £15,000.
5. The expected benefits for patients on delivery of this project are:	Further development of HCPs with specific knowledge around insulin adjustment in Type 2 Diabetes to enable them to better support their patients. Provision of a virtual interactive training course, making education more accessible to a greater number of patients. Improved delivery of education through remote learning.
6. The expected benefits for the partner organisation(s) on delivery of this project are:	Potential increase in number of sites enrolled in DAFNE through extended reach into Type 2 Diabetes and subsequent revenue that this may generate.
7. The expected benefits for Lilly UK on delivery of this are:	Lilly Diabetes brand reputation through collaborative working with DAFNE. Improved patient experience with for PwT2D on insulin (including but not limited to Lilly's insulins), potentially improving patient adherence to therapy.